Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial

Journal of Clinical Oncology

Volumn 24, Issue 5, 2006, Pages 727-735

  Koukourakis, Michael I ^a   Bentzen, Søren M ^a   Giatromanolaki, Alexandra ^a   Wilson, George D ^a   Daley, Frances M ^a   Saunders, Michele I ^a   Dische, Stanley ^a   Sivridis, Efthimios ^a   Harris, Adrian L ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; HYPOXIA INDUCIBLE FACTOR 2, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR 2, ALPHA SUBUNIT; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GENE CONTROL; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT FAILURE; BIOPSY; BIOSYNTHESIS; CELL HYPOXIA; GENE EXPRESSION PROFILING; HEAD AND NECK TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOPSY; CARBONIC ANHYDRASES; CELL HYPOXIA; DOSE FRACTIONATION; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33644849887     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.7474     Document Type: Article

References (40)

1. Bernier J, Bentzen SM: Altered fractionation and combined radio-chemotherapy approaches: Pioneering new opportunities in head and neck oncology. Eur J Cancer 39:560-571, 2003
2. Withers HR, Taylor JMG, Maciejewski B: The hazards of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131-146, 1988
3. Bentzen SM: Quantitative clinical radiobiology. Acta Oncol 32:259-275, 1993
4. Horiot JC, Bontemps P, van den Bogaert W, et al: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 44:111-121, 1997
5. Fu KK, et al: Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
6. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933-940, 2003
7. Dische S, Saunders M, Barrett A, et al: A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123-136, 1997
8. Bentzen SM: Repopulation in radiation oncology: Perspectives of clinical research. Int J Radiat Biol 79:581-585, 2003
9. Dische S: A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys 20:147-152, 1991
10. Stone HB, Brown JM, Phillips TL, et al: Oxygen in human tumors: Correlations between methods of measurement and response to therapy: Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 136:422-434, 1993
11. Kaanders JH, Wijffels KI, Marres HA, et al: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074, 2002
12. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10-21, 1996
13. Denekamp J, Joiner MC: The potential benefit from a perfect radiosensitizer and its dependence on reoxygenation. Br J Radiol 55:657-663, 1982
14. Petersen C, Eicheler W, Frommel A, et al: Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 79:469-477, 2003
15. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: hypoxia inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002
16. Hui EP, Chan AT, Pezzella F, et al: Coexpression of hypoxia inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595-2604, 2002
17. Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia inducible factor-1 alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911-2916, 2001
18. Goda N, Ryan HE, Khadivi B, et al: hypoxia inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23:359-369, 2003
19. Wykoff CC, Beasley NJ, Watson PH, et al: Hypoxia inducible regulation of tumor associated carbonic anhydrases. Cancer Res 60:7075-7083, 2001
20. Loncaster JA, Harris AL, Davidson SE, et al: M. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394-6399, 2001
21. Sowter HM, Raval R, Moore J, et al: Predominant role of hypoxia inducible transcription factor Hif-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63:6130-6134, 2003
22. Hu CJ, Wang LY, Chodosh LA, et al: Differential roles of hypoxia inducible factor 1 alpha (HIF-1 alpha) and HIF-2 alpha in hypoxic gene regulation. Mol Cell Biol 23:9361-9374, 2003
23. Talks KL, Turley H, Gatter KC, et al: The expression and distribution of the hypoxia inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421, 2000
24. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-regulated Carbonic Anhydrase-9 (CA9) Relates to Poor Vascularization and Resistance of Squamous Cell Head and Neck Cancer to Chemoradiotherapy. Clin Cancer Res 7:3399-3403, 2001
25. Giatromanolaki A, Koukourakis Ml, Sivridis E, et al: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85:881-890, 2001
26. Sivridis E, Giatromanolaki A, Gatter KC, et al: Association of hypoxia inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-1063, 2002
27. Giatromanolaki A, Sivridis E, Kouskoukis C, et al: hypoxia inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13:493-501, 2003
28. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999
29. Harris AL: Hypoxia: A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47, 2002
30. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732, 2003
31. Achermann RE, Ohlerth SM, Rohrer Bley C, et al: Oxygenation of spontaneous canine tumors during fractionated radiation therapy. Strahlenther Onkol 180:297-305, 2004
32. Dietz A, Vanselow B, Rudat V, et al: Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone. Head Neck 25:50-58, 2003
33. Auberger T, Thurriegl B, Freude T, et al: Oxygen tension in transplanted mouse osteosarcomas during fractionated high-LET- and low-LET radiotherapy-predictive aspects for choosing beam quality? Strahlenther Onkol 175:52-56, 1999 (suppl 2)
34. Urano M, Nishimura Y, Yaes R: The relative significance of repopulation and hypoxic clonogens in the fractionated radiotherapy of a mouse tumor. Radiat Res 142:204-211, 1995
35. Dobrowsky W, Naude J: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 57:119-124, 2000
36. Gandara DR, Lara PN Jr., Goldberg Z, et al: Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29:102-109, 2002 (suppl 4)
37. Saunders MI, Hoskin PJ, Pigott K, et al: Accelerated radiotherapy, carbogen and nicotinamide (ARGON) in locally advanced head and neck cancer: A feasibility study. Radiother Oncol 45:159-166, 1997
38. Henk JM, Bishop K, Shepherd SF: Treatment of head and neck cancer with CHART and nimorazole: Phase II study. Radiother Oncol 66:65-70, 2003
39. Lee DJ, Cosmatos D, Marcial VA, et al: Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32:567-576, 1995
40. Lee DJ, Fu KK, Cooper JS, et al: End of an era or not? That is the question: In response to Dr JM Brown. Int J Radiat Oncol Biol Phys 32:1263-1264, 1995